Table 1

Patient, disease, and transplantation characteristics

CharacteristicsNo. (%)
P
Double UCB TransplantationSingle UCB Transplantation
No. of patients 303 106  
No. of transplantation teams 45 47  
Median recipient age, y (range) 43 (16-71) 33 (16-69) < .0001 
    16-20 32 (11) 27 (25)  
    21-30 53 (17) 20 (19)  
    31-40 48 (16) 21 (20)  
    41-50 51 (17) 15 (14)  
    51-60 76 (25) 14 (13)  
    61-71 43 (14) 9 (8)  
Recipient CMV serostatus transplantation   .52 
    Negative 93 (31) 35 (33)  
    Positive 193 (64) 68 (64)  
    Not reported 17 (6) 3 (3)  
Disease   .34 
    Acute myeloid leukemia 215 (71) 70 (66)  
    Acute lymphoblastic leukemia 88 (29) 36 (34)  
Disease status   .006 
    First complete remission 135 (45) 38 (36)  
    Second complete remission 100 (33) 31 (29)  
    Third complete remission 20 (7) 5 (5)  
    Relapse 48 (16) 32 (30)  
Donor-recipient HLA match   .07 
    6/6 13 (4) 10 (9)  
    5/6 80 (26) 33 (31)  
    4/6 210 (69) 63 (59)  
Conditioning regimen   < .0001 
    Myeloablative    
        TBI + cyclophosphamide* 94 (31) 49 (46)  
        TBI + other agents** 22 (7) 10 (9)  
        Busulfan + cyclophosphamide*** 7 (2) 8 (8)  
        Busulfan + other agents**** 16 (5) 10 (9)  
    Reduced intensity    
        TBI + cyclophosphamide + fludarabine 119 (39) 20 (19)  
        Busulfan + fludarabine†† 5 (2) 2 (2)  
        Melphalan + fludarabine††† 35 (12) 5 (5)  
        Cyclophosphamide + fludarabine†††† 5 (2) 2 (2)  
GVHD prophylaxis   < .0001 
    Tacrolimus alone or with steroid 8 (3) 10 (9)  
    Tacrolimus + methotrexate 6 (2) 9 (8)  
    Tacrolimus + mycophenolate mofetil 85 (28) 20 (19)  
    Cyclosporine alone or with steroid 8 (3) 19 (8)  
    Cyclosporine + methotrexate 1 (< 1) 6 (6)  
    Cyclosporine + mycophenolate mofetil 176 (58) 40 (38)  
    Mycophenolate mofetil + steroid 1 (< 1)   
    Not reported 18 (6) 2 (2)  
TNC cryopreserved, ×107/kg (sum of units)   < .0001 
    Median dose (range) 4.5 (2.6-15) 3.5 (2.5-8.6)  
    2.5-3.0 18 (6) 26 (28)  
    3.0-4.0 77 (25) 47 (43)  
    > 4.0 202 (67) 33 (30)  
    Not reported 6 (2)   
TNC infused, ×107/kg (sum of units)   < .0001 
    Median dose (range) 3.7 (1.8-15.8) 2.8 (1.0-7.5)  
    < 2.5 28 (9) 30 (28)  
    2.5-3.0 49 (16) 35 (33)  
    3.0-4.0 108 (36) 21 (20)  
    > 4.0 111 (37) 20 (19)  
    Not reported 6 (2)   
Year of transplantation   < .0001 
    2002-2004 40 (14) 32 (30)  
    2005-2009 263 (86) 74 (70)  
Median follow-up, mo (range) 23 (3-74) 17 (3-62)  
CharacteristicsNo. (%)
P
Double UCB TransplantationSingle UCB Transplantation
No. of patients 303 106  
No. of transplantation teams 45 47  
Median recipient age, y (range) 43 (16-71) 33 (16-69) < .0001 
    16-20 32 (11) 27 (25)  
    21-30 53 (17) 20 (19)  
    31-40 48 (16) 21 (20)  
    41-50 51 (17) 15 (14)  
    51-60 76 (25) 14 (13)  
    61-71 43 (14) 9 (8)  
Recipient CMV serostatus transplantation   .52 
    Negative 93 (31) 35 (33)  
    Positive 193 (64) 68 (64)  
    Not reported 17 (6) 3 (3)  
Disease   .34 
    Acute myeloid leukemia 215 (71) 70 (66)  
    Acute lymphoblastic leukemia 88 (29) 36 (34)  
Disease status   .006 
    First complete remission 135 (45) 38 (36)  
    Second complete remission 100 (33) 31 (29)  
    Third complete remission 20 (7) 5 (5)  
    Relapse 48 (16) 32 (30)  
Donor-recipient HLA match   .07 
    6/6 13 (4) 10 (9)  
    5/6 80 (26) 33 (31)  
    4/6 210 (69) 63 (59)  
Conditioning regimen   < .0001 
    Myeloablative    
        TBI + cyclophosphamide* 94 (31) 49 (46)  
        TBI + other agents** 22 (7) 10 (9)  
        Busulfan + cyclophosphamide*** 7 (2) 8 (8)  
        Busulfan + other agents**** 16 (5) 10 (9)  
    Reduced intensity    
        TBI + cyclophosphamide + fludarabine 119 (39) 20 (19)  
        Busulfan + fludarabine†† 5 (2) 2 (2)  
        Melphalan + fludarabine††† 35 (12) 5 (5)  
        Cyclophosphamide + fludarabine†††† 5 (2) 2 (2)  
GVHD prophylaxis   < .0001 
    Tacrolimus alone or with steroid 8 (3) 10 (9)  
    Tacrolimus + methotrexate 6 (2) 9 (8)  
    Tacrolimus + mycophenolate mofetil 85 (28) 20 (19)  
    Cyclosporine alone or with steroid 8 (3) 19 (8)  
    Cyclosporine + methotrexate 1 (< 1) 6 (6)  
    Cyclosporine + mycophenolate mofetil 176 (58) 40 (38)  
    Mycophenolate mofetil + steroid 1 (< 1)   
    Not reported 18 (6) 2 (2)  
TNC cryopreserved, ×107/kg (sum of units)   < .0001 
    Median dose (range) 4.5 (2.6-15) 3.5 (2.5-8.6)  
    2.5-3.0 18 (6) 26 (28)  
    3.0-4.0 77 (25) 47 (43)  
    > 4.0 202 (67) 33 (30)  
    Not reported 6 (2)   
TNC infused, ×107/kg (sum of units)   < .0001 
    Median dose (range) 3.7 (1.8-15.8) 2.8 (1.0-7.5)  
    < 2.5 28 (9) 30 (28)  
    2.5-3.0 49 (16) 35 (33)  
    3.0-4.0 108 (36) 21 (20)  
    > 4.0 111 (37) 20 (19)  
    Not reported 6 (2)   
Year of transplantation   < .0001 
    2002-2004 40 (14) 32 (30)  
    2005-2009 263 (86) 74 (70)  
Median follow-up, mo (range) 23 (3-74) 17 (3-62)  

TBI indicates total body irradiation; TNC, total nucleated cell dose; and UCB, umbilical cord blood.

*

N = 4 double UCB recipients and N = 13 single UCB recipients received ATG.

**

N = 4 double UCB recipients and N = 4 single UCB recipients received ATG.

***

N = 3 double UCB recipients and N = 6 single UCB recipients received ATG.

****

N = 9 double UCB recipients and N = 6 single UCB recipients received ATG.

N = 35 double UCB recipients and N = 4 single UCB recipients received ATG; TBI dose = 200 cGy

††

N = 2 double UCB recipients and N = 1 single UCB recipients received ATG.

†††

N = 30 double UCB recipients and N = 4 single UCB recipients received ATG.

††††

N = 2 double UCB recipients and N = 1 single UCB recipients received ATG.

Close Modal

or Create an Account

Close Modal
Close Modal